MKNK1 and acute myeloid leukemia: In fact, several studies have shown that the oncogenic activity of eIF4E can be targeted by inhibiting MNK1/2-induced phosphorylation of eIF4E at serine 209 in different malignancies, including AML, which leads to potent anti-tumor responses in vitro and in vivo [30, 46–48].